Maud Kamal manages and coordinates precision medicine and European projects at Institut Curie where she is also in charge of the scientific management of the Molecular Tumour Board. She is currently involved in several projects among which RAIDs (Rational Molecular Assessment Innovative Drug selection), the first biobanking study for cervical cancer patients in Europe aiming towards implementing innovative treatment strategies based on patient molecular stratification. She has also been in charge of the management of the SHIVA trial, the first randomised precision medicine clinical trial.

Following a BSc and a Teaching Diploma in Sciences from the American University of Beirut, Lebanon, in 1999, she received a scholarship for a PhD programme in molecular and cell biology from the University of Sherbrooke, Canada. After receiving her MSc in Cell Biology, she pursued her PhD studies in Molecular and Cellular Biology at the University of Paris XII.  In 2007, she joined Institut Cochin in France for a Postdoctoral position and worked in collaboration with the research institute of SERVIER. She also holds a University Diploma in « Economic Valorisation of Research » from University of Paris VI.

Maud Kamal has published over 40 peer-reviewed papers in international journals.